LPTX News and Press, Leap Therapeutics Inc. From 05/15/23

2023-05-15 10:17:30 ET Leap Therapeutics press release ( NASDAQ: LPTX ): Q1 GAAP EPS of -$0.32 misses by $0.23 . Net Loss was $41.9 million for the first quarter 2023, compared to $10.4 million for the same period in 2022. Cash and cash equivalents totaled $102.0...

Leap Therapeutics Reports First Quarter 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting PR Newswire CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Leap Therapeutics,...

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients PR Newswire CAMBRIDGE, Mass. , April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology com...

2023-03-24 07:21:56 ET Leap Therapeutics press release ( NASDAQ: LPTX ): Q4 GAAP EPS of -$0.11 in-line. Cash and cash equivalents totaled $65.5 million at December 31, 2022, which excludes the approximately $50 million cash received from the Flame Biosciences acquisition. ...

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 PR Newswire DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- Leap Therapeutics, In...

Leap Therapeutics ( NASDAQ: LPTX ) shares recovered Thursday after Japan-based Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) posted Phase 3 data for its Claudin 18.2 (CLDN18.2) targeted monoclonal antibody, zolbetuximab. Leap ( LPTX ) shares sold off on Tuesday after ann...

Oncology-focused biotech Leap Therapeutics ( NASDAQ: LPTX ) lost ~2% pre-market Tuesday after announcing an agreement with privately-held Flame Biosciences to acquire the latter in an all-stock transaction. The deal will add Flame's ~$50M of year-end net cash, its Phase 2 cancer c...

Leap Therapeutics Acquires Flame Biosciences PR Newswire Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding a...